TABUTEAU HERRIOT 4

What Happened Tabuteau Herriot, CEO of Axsome Therapeutics, was granted 54,623 restricted stock units (RSUs) on 2026-02-26 (transaction code A). The grant was reported at a $0.00 acquisition price on the Form 4 — RSUs are a derivative award that convert to common shares only upon vesting or other triggering events, so no cash was exchanged and no shares were immediately delivered.

Key Details

• Transaction date and type: 2026-02-26 — Grant/Award of RSUs (Code A).
• Units and price: 54,623 RSUs at $0.00 per unit (reported value $0 on Form 4).
• Shares owned after transaction: Not specified in the filing.
• Vesting and delivery (from footnotes): 25% vests on the 1-year anniversary; remaining RSUs vest in three substantially equal annual installments, with full vesting by Feb 26, 2030. Vested shares will be delivered upon the earlier of (i) a Change in Control, (ii) the reporting person’s separation of service (including termination, death, or total and permanent disability), or (iii) seven years from the grant date.
• Filing timeliness: Reported on 2026-02-27 for a 2026-02-26 transaction — appears timely.
• Other notes: No 10b5-1 plan, tax-withholding, or immediate cashless exercise indicated in the filing.

Context This was a compensation equity grant (RSUs), not an open‑market purchase or sale. RSUs represent a contingent right to receive one share per unit upon meeting vesting or other conditions; they do not convey immediate ownership or proceeds until vested/delivered. For retail investors, such awards are common executive compensation and should be interpreted differently than insider purchases or sales.